Adenovirus/alphavirus hybrid vector for the effective...

Details Adenovirus/alphavirus hybrid vector for the effective... Adenovirus/alphavirus hybrid vector for the effective...

2005-05-18

2010-12-14

Sajjadi, Fereydoun G (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S199100, C435S455000

Reexamination Certificate

active

07850957

ABSTRACT:
The present invention relates to a genic expression adenoviral hybrid vector characterized in that it contains at least the following elements, oriented in the direction 5′ to 3′: i. a first chain of adenoviral origin comprising a first inverted terminal repeat (ITR) sequence and a signal sequence for packaging of the adenovirus; ii. a first non-encoding stuffer sequence; iii. a sequence corresponding to a tissue specific promoter; iv. a chain of cDNA derived from an alphavirus, the sequence of which is partly complementary to an alphaviral RNA sequence, comprising at least a sequence encoding for at least one exogenous gene of interest; v. a polyadenylation sequence; and vi. a second adenoviral inverted terminal repeat (ITR) sequence, it preferably relates to an adenoviral hybrid vector comprising as exogenous gene of interest the therapeutic gene of mammalian interleukin IL-12 and even more preferably human interleukin hIL-12; and to the use of the hybrid vector in a process for transferring genetic material to a cell, particularly a tumor cell that preferably expresses alpha-fetoprotein (AFP), and to its use for inducing an immune response against foreign antigens.

REFERENCES:
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 5985846 (1999-11-01), Kochanek
patent: 6238858 (2001-05-01), Ramsey et al.
patent: 6566093 (2003-05-01), Liljestrom et al.
patent: 6824770 (2004-11-01), Falck-Pedersen
patent: 7199279 (2007-04-01), Rapp
patent: 2002/0081277 (2002-06-01), Trinchieri et al.
patent: 2002/0164799 (2002-11-01), Little et al.
patent: 2004/0005293 (2004-01-01), Vandendriessche et al.
patent: 2005/0255511 (2005-11-01), Debinski et al.
patent: 0797678 (2001-03-01), None
patent: 0651890 (2003-04-01), None
patent: 9815636 (1998-04-01), None
patent: 9822143 (1998-05-01), None
patent: 9925858 (1999-05-01), None
patent: WO 99/25859 (1999-05-01), None
patent: 9932647 (1999-07-01), None
patent: 0046360 (2000-08-01), None
patent: 0073424 (2000-12-01), None
patent: 0172341 (2001-10-01), None
patent: 0238782 (2002-05-01), None
Rayner et al., “Alphavirus Vectors and Vaccination,” Rev. Med. Virol., vol. 12, (2002) pp. 279-296.
Volpers et al., “Adenoviral Vectors for Gene Transfer and Therapy,” J. Gene Med., vol. 6, (2004) pp. S164-S171.
Schiedner et al., “Variables Affecting in vivo Performance of High-Capacity Adenoviral Vectors,” J. Virol., vol. 76, No. 4, (2002) pp. 1600-1609.
Strauss, James H., et al., The Alphaviruses: Gene Expression, Replication, and Evolution, Microbiological Reviews, 1994, pp. 491-562, vol. 58, No. 3.
Glasgow, Gwendoline M., et al., The Semliki Forest virus vector induces p53-independent apoptosis, Journal of General Virology, 1998, pp. 2405-2410, vol. 79.
Liljestrom, Peter, et al., A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon, Bio/Technology, 1991, pp. 1356-1361, vol. 9.
Shi, Yu-Jun, et al., Construction of a targeting adenoviral vector carrying AFP promoter for expression EGFP gene in AFP-producing hepatocarcinoma cell, World Journal of Gastroenterology, 2004, pp. 186-189, vol. 10, No. 2.
Kaneko, Shuichi, et al., Adenovirus-mediated Gene Therapy of Hepatocellular Carcinoma Using Cancer-specific Gene Expression, Cancer Research, 1995, pp. 5283-5287, vol. 55.
Guan, Min, et al., Increased Efficacy and Safety in the Treatment of Experimental Liver Cancer with a Novel Adenovirus-Alphavirus Hybrid Vector, Cancer Research, 2006, pp. 1620-1629, vol. 66, No. 3.
McGrory, W.J., et al., Short Communications, A Simple Technique for the Rescue of Early Region I Mutations into Infectious Human Adenovirus Type 5, Virology, 1988, pp. 614-617, vol. 163.

Affiliated with

Also associated with

Rating

Adenovirus/alphavirus hybrid vector for the effective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adenovirus/alphavirus hybrid vector for the effective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus/alphavirus hybrid vector for the effective... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4172200